Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 6 de 6
Filter
1.
Rev. chil. endocrinol. diabetes ; 6(4): 143-146, oct.2013. ilus, tab
Article in Spanish | LILACS | ID: lil-780401

ABSTRACT

Twelve percent of Cushing syndromes (CS) are caused by ectopic ACTH secretion. We report two cases of the condition. A 57 years old woman with an ectopic CS caused by a bronchial carcinoid tumor. After the tumor excision, the patient had a favorable evolution. A 63 years old woman consulting for cough, dyspnea and weight loss causes by a small cell lung cancer. The patient presented hyperglycemia, hypokalemia and metabolic alcalosis. The laboratory showed a severe hypercortisolism with elevated ACTH levels. The metabolic condition did not subside after the first course of chemotherapy and the patient died due to an infectious complication...


Subject(s)
Humans , Female , Middle Aged , Carcinoma, Small Cell , Lung Neoplasms , ACTH Syndrome, Ectopic/etiology , Cushing Syndrome/etiology
2.
Rev. Méd. Clín. Condes ; 21(6): 930-934, nov. 2010. tab
Article in Spanish | LILACS | ID: biblio-999233

ABSTRACT

La Orbitopatía de Graves se presenta clínicamente en aproximadamente 50 por ciento de los casos de Enfermedad de Graves. La mayoría de las veces es leve y sólo en menos del 5 por ciento pone en riesgo la visión, pese a lo cual deteriora significativamente la calidad de vida de los pacientes. Hasta el momento no se conoce totalmente la patogenia, siendo posiblemente el receptor de TSH el blanco de la autoinmunidad. En cuanto al tratamiento, las medidas preventivas como lograr el eutiroidismo y la suspensión del tabaco son útiles en los distintos grados de la enfermedad. Para los casos más severos se han investigado diferentes medicamentos pero ninguno ha demostrado ser superior a los Glucocorticoides. Actualmente los consensos concuerdan en que es imprescindible clasificar al paciente según grado de actividad y severidad para orientar la terapia con mayor eficacia. Las investigaciones en curso pretenden encontrar una droga que supere el rendimiento existente


Graves' orbitopathy occurs clinically in approximately 50 percent of Graves' Disease. Most often it is mild and only less than 5 percent can threaten vision, despite which it significantly impairs the quality of life of this patients. So far its pathogenesis is not completely understood, but possibly TSH receptor is the target of autoimmunity. In relation to treatment, preventive measures such as achieving euthyroidism and the suspension of tobacco are useful in varying degrees of the disease. For more severe cases, different drugs have been investigated but none has shown superior efficacy to that of Glucocorticoids. Currently, different consensus agrees that it is essential to classify the patient according to levels of activity and severity to guide therapy more effectively. Ongoing investigations aim to find a drug that exceeds the existing performance


Subject(s)
Humans , Graves Ophthalmopathy/etiology , Graves Ophthalmopathy/therapy , Thyroid Diseases/complications , Thyroid Diseases/therapy , Severity of Illness Index , Somatostatin/analogs & derivatives , Somatostatin/therapeutic use , Smoking/adverse effects , Tobacco Use Cessation , Graves Ophthalmopathy/immunology , Glucocorticoids/therapeutic use
3.
Rev. méd. Chile ; 134(4): 475-480, abr. 2006. ilus, tab
Article in Spanish | LILACS | ID: lil-428548

ABSTRACT

Antineutrophil cytoplasmic antibody (ANCA)-positive vasculitis is an uncommon complication of the use of propylthiouracil. When it occurs, it affects multiple organs as any systemic vasculitis. We report three females and one male, aged 30, 40, 43 and 41 years respectively, that after a lapse of 12 to 28 months of propylthiouracil use, presented clinical signs of vasculitis. All had high titers of ANCA against myeloperoxidase. In three patients, a skin biopsy confirmed the diagnosis. The condition subsided when propylthiouracil was discontinued, but one female patient required the use of prednisone.


Subject(s)
Adult , Female , Humans , Male , Antibodies, Antineutrophil Cytoplasmic/drug effects , Antithyroid Agents/adverse effects , Propylthiouracil/adverse effects , Vasculitis/chemically induced , Antibodies, Antineutrophil Cytoplasmic/blood , Antithyroid Agents/therapeutic use , Biomarkers/blood , Biopsy , Hyperthyroidism/drug therapy , Propylthiouracil/therapeutic use , Vasculitis/blood , Vasculitis/pathology
SELECTION OF CITATIONS
SEARCH DETAIL